Comparative Pharmacology
Head-to-head clinical analysis: AFRINOL versus NAPHCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFRINOL versus NAPHCON A.
AFRINOL vs NAPHCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
Naphcon-A combines naphazoline, an alpha-adrenergic receptor agonist, and pheniramine, a histamine H1-receptor antagonist. Naphazoline constricts conjunctival blood vessels via alpha-adrenergic stimulation, reducing redness and edema. Pheniramine blocks histamine effects, alleviating itching and allergic reactions.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
1-2 drops instilled into the conjunctival sac every 3-4 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Naphazoline: ~2-3 hours; antazoline: ~3-4 hours. Clinical context: ocular administration, systemic absorption minimal.
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (CrCl <30 mL/min).
Primarily renal excretion of unchanged drug and metabolites; naphazoline <10% unchanged, antazoline ~30% unchanged. Biliary/fecal elimination negligible.
Category C
Category C
Decongestant
Ophthalmic Antihistamine/Decongestant